In preparation for anticipated 2026 launches in the US for an omalizumab biosimilar, we are monitoring the developments of some of the leading candidates. Top-line, preliminary phase 3 results were released June 25 by partners Amneal Pharmaceuticals and Kashiv Biosciences for ADL-018, their progressing omalizumab biosimilar. In their double-blinded, randomized clinical efficacy and safety trial … Continue reading Amneal and Kashiv Announce Progress in Development of Omalizumab Biosimilar